Third-Line Treatment for GIST
Regorafenib 160 mg orally once daily for 3 weeks on/1 week off is the standard third-line therapy for patients with advanced or metastatic GIST who have progressed on both imatinib and sunitinib 1, 2.
Evidence Basis
The recommendation for regorafenib as third-line therapy is supported by the highest level of evidence (Level I, Grade A) from both the 2022 ESMO-EURACAN-GENTURIS guidelines and the 2025 British Sarcoma Group guidelines 1, 2. This designation is based on a prospective, placebo-controlled, randomized trial demonstrating significant progression-free survival (PFS) benefit with regorafenib in this patient population 1, 2.
Mechanism and Rationale
Regorafenib is a multikinase inhibitor with a critical mechanistic advantage over earlier-line therapies: it effectively inhibits tumors harboring secondary mutations in the activation loop of KIT, particularly exon 17 mutations 2. This is the key distinction that makes regorafenib effective after imatinib and sunitinib failure, as these secondary mutations are common resistance mechanisms.
Dosing Specifics
- Standard dose: 160 mg orally once daily
- Schedule: 3 weeks on treatment, 1 week off (3/1 schedule)
- Duration: Continue until disease progression or unacceptable toxicity
Clinical Considerations
When to Use Third-Line Therapy
Initiate regorafenib only after confirmed progression on both imatinib and sunitinib 1. This confirmation is important because continuing TKI therapy even with slow progression may be beneficial in some patients with indolent disease.
Alternative Options in Special Circumstances
For SDH-deficient GISTs: These tumors are insensitive to imatinib but may have some sensitivity to both sunitinib and regorafenib 1. Regorafenib remains an appropriate third-line option in this molecular subtype.
For patients with prior response to imatinib: Consider imatinib rechallenge as an alternative option (Level II, Grade B evidence) 1. Controlled evidence shows that patients who previously progressed on imatinib may benefit when rechallenged with the same drug.
Continuation of TKI beyond progression: If no other options are immediately available, continuing the current TKI may slow progression compared to stopping treatment entirely, at least in patients with slow disease kinetics 1.
Common Pitfalls
- Don't skip mutation testing: While not required for regorafenib initiation, understanding the mutational profile helps predict response and plan subsequent therapy
- Don't use regorafenib before documenting progression on sunitinib: The evidence base specifically requires failure of both prior lines
- Monitor for side effects: Regorafenib has a distinct toxicity profile including fatigue, hand-foot skin reaction, hypertension, and hepatotoxicity that requires proactive management
What Comes Next
After regorafenib failure, ripretinib 150 mg daily is the standard fourth-line treatment (Level I, Grade A) 1, 2. Ripretinib is a "switch kinase" inhibitor with a unique mechanism of action that works allosterically rather than at the ATP-binding site, providing activity even after multiple prior TKI failures.
Real-World Performance
Real-world data suggests that patients who received prior imatinib or sunitinib alone before regorafenib had numerically longer duration of therapy compared to those who received both sequentially (142.5 vs 95 days median) 3. However, the sequential use of all three agents remains the evidence-based standard approach.